Covered recipient · General Payments record
YAEL RACHEL ELFASSY
Allopathic & Osteopathic Physicians Pediatrics
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$31.57
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $31.57 | 2 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| SANOFI PASTEUR INC. | $31.57 | 2 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
YAEL RACHEL ELFASSY
NPI 1598081002 · CMS profile ID 253025
Allopathic & Osteopathic Physicians / Pediatrics
SAVANNAH, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- YAEL RACHEL ELFASSY, NPI 1598081002, CMS profile ID 253025, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1598081002?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $31.57 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| SANOFI PASTEUR INC. | $17.42 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937307117 | CMS |
| SANOFI PASTEUR INC. | $14.15 | 04/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937307105 | CMS |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2022 | $31.57 | 2 |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2022
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $908,633.80 | 124 |
| PY2024 | Principal investigator | $942,634.71 | 86 |
| PY2023 | Recipient | $511.38 | 1 |
| PY2023 | Principal investigator | $550,439.29 | 47 |
| PY2022 | Principal investigator | $196,273.44 | 19 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
86 records in PY2024
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $840.00 | 12/31/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder | No dispute reported | 06/30/2026 | 1100764217 |
| Principal investigator 1 | ABBVIE INC. | $602.00 | 12/31/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis | No dispute reported | 06/30/2026 | 1100764219 |
| Principal investigator 1 | ABBVIE INC. | $3,167.34 | 12/31/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH | M21-465 Vraylar Ph3 Autism Spectrum Patients (2000-301-009) | No dispute reported | 06/30/2026 | 1100766983 |
| Principal investigator 1 | ModernaTX, Inc. | $12,381.00 | 12/23/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192108 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 12/18/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100761709 |
| Principal investigator 1 | ABBVIE INC. | $12,526.62 | 12/18/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100761711 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,509.47 | 12/13/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1143156636 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $71,474.40 | 12/05/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128696764 |
| Principal investigator 1 | ABBVIE INC. | $7,500.00 | 12/02/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of?CVL-231?(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100757355 |
| Principal investigator 1 | ModernaTX, Inc. | $94,044.00 | 11/27/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192102 |
| Principal investigator 1 | ModernaTX, Inc. | $1,873.80 | 11/22/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154067 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $10,000.00 | 11/22/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128696768 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,700.00 | 11/22/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age. | No dispute reported | 06/30/2026 | 1128696770 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,504.78 | 11/22/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128705149 |
| Principal investigator 1 | ABBVIE INC. | $1,750.00 | 11/20/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100755965 |
| Principal investigator 1 | ABBVIE INC. | $3,849.38 | 11/20/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100755967 |
| Principal investigator 1 | ModernaTX, Inc. | $700.00 | 11/15/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154069 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 11/01/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of00FFCVL-23100FF(Emraclidine) in Adult Participants With Schizophrenia | No dispute reported | 06/30/2026 | 1100751475 |
| Principal investigator 1 | Eli Lilly and Company | $15,905.00 | 11/01/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137354516 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $8,802.82 | 10/25/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128705151 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $500.00 | 10/24/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1143139360 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $721.17 | 10/24/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1143139364 |
| Principal investigator 1 | ModernaTX, Inc. | $9,050.00 | 10/24/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192096 |
| Principal investigator 1 | Corium, LLC | $12,329.25 | 10/09/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1118400182 |
| Principal investigator 1 | ModernaTX, Inc. | $931.50 | 10/01/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154063 |
| Principal investigator 1 | ModernaTX, Inc. | $484.81 | 10/01/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1147154065 |
| Principal investigator 1 | ModernaTX, Inc. | $2,550.00 | 09/13/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1147154061 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $400.00 | 09/13/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730610 |
| Principal investigator 1 | ABBVIE INC. | $4,768.20 | 09/04/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100741058 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,801.66 | 09/04/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730520 |
| Principal investigator 1 | ModernaTX, Inc. | $668.25 | 08/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192082 |
| Principal investigator 1 | ModernaTX, Inc. | $598.68 | 08/27/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age | No dispute reported | 06/30/2026 | 1147192084 |
| Principal investigator 1 | Eli Lilly and Company | $2,415.00 | 08/20/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MEVIDALEN IN PATIENTS WITH ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1137356058 |
| Principal investigator 1 | Corium, LLC | $38,669.42 | 08/16/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Efficacy and Safety Study w/ Azstarys in Children With ADHD | No dispute reported | 06/30/2026 | 1118400022 |
| Principal investigator 1 | Corium, LLC | $26,316.60 | 08/07/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1118400126 |
| Principal investigator 1 | PFIZER INC. | $475.00 | 08/06/2024 | Non-covered Recipient Entity CenExel iResearch LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131032770 |
| Principal investigator 1 | ABBVIE INC. | $6,075.00 | 08/02/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100734456 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,506.36 | 07/17/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730518 |
| Principal investigator 1 | ModernaTX, Inc. | $3,720.60 | 07/12/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192064 |
| Principal investigator 1 | ABBVIE INC. | $1,034.10 | 07/11/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100728746 |
| Principal investigator 1 | Corium, LLC | $6,301.05 | 07/11/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1118400124 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1,500.00 | 07/10/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumateperone in Pediatric Patients, Ages 5 to less than 13 Years, Diagnosed with Autism Spectrum Disorder | No dispute reported | 06/30/2026 | 1143127311 |
| Principal investigator 1 | ABBVIE INC. | $15,930.00 | 07/05/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100727598 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,458.35 | 07/03/2024 | Non-covered Recipient Entity Cenexel Iresearch Llc | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128730516 |
| Principal investigator 1 | PFIZER INC. | $133,733.49 | 06/25/2024 | Non-covered Recipient Entity CenExel iReasearch LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131066980 |
| Principal investigator 1 | ABBVIE INC. | $521.10 | 06/12/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100723346 |
| Principal investigator 1 | ABBVIE INC. | $449.55 | 06/12/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100723354 |
| Principal investigator 1 | ABBVIE INC. | $2,160.00 | 06/12/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100723356 |
| Principal investigator 1 | ABBVIE INC. | $31,708.80 | 06/06/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100722316 |
| Principal investigator 1 | Corium, LLC | $14,958.00 | 06/04/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1118399982 |
| Principal investigator 1 | ModernaTX, Inc. | $6,847.20 | 05/29/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154059 |
| Principal investigator 1 | Amgen Inc. | $8,836.15 | 05/24/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Phase P3 Pediatric Study EM | No dispute reported | 06/30/2026 | 1096315459 |
| Principal investigator 1 | PFIZER INC. | $4,250.04 | 05/24/2024 | Non-covered Recipient Entity CenExel iResearch LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131080389 |
| Principal investigator 1 | PFIZER INC. | $7,114.25 | 05/24/2024 | Non-covered Recipient Entity CenExel iReasearch LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1131080395 |
| Principal investigator 1 | ABBVIE INC. | $40,257.00 | 05/09/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100717616 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,000.00 | 05/08/2024 | Non-covered Recipient Entity Cenexel Iresearch Atlanta | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128711399 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,000.00 | 05/08/2024 | Non-covered Recipient Entity Cenexel Iresearch Atlanta | Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | No dispute reported | 06/30/2026 | 1128711401 |
| Principal investigator 1 | Corium, LLC | $15,036.68 | 05/01/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Efficacy and Safety Study w/ Azstarys in Children With ADHD | No dispute reported | 06/30/2026 | 1118399932 |
| Principal investigator 1 | ModernaTX, Inc. | $8,500.00 | 04/26/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. | No dispute reported | 06/30/2026 | 1147154039 |
| Principal investigator 1 | ABBVIE INC. | $313.20 | 04/25/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100714994 |
| Principal investigator 1 | ABBVIE INC. | $1,890.00 | 04/25/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100715010 |
| Principal investigator 1 | ABBVIE INC. | $1,012.50 | 04/25/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100715012 |
| Principal investigator 1 | Amgen Inc. | $9,563.70 | 04/20/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Ph3 Pediatric CM Study | No dispute reported | 06/30/2026 | 1096315013 |
| Principal investigator 1 | ModernaTX, Inc. | $2,718.90 | 04/10/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154041 |
| Principal investigator 1 | ModernaTX, Inc. | $83.75 | 04/10/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154043 |
| Principal investigator 1 | ABBVIE INC. | $20,563.20 | 04/04/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100711958 |
| Principal investigator 1 | ABBVIE INC. | $432.00 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100710266 |
| Principal investigator 1 | ABBVIE INC. | $1,653.75 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100710276 |
| Principal investigator 1 | ABBVIE INC. | $1,350.00 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100710278 |
| Principal investigator 1 | ABBVIE INC. | $1,732.05 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100710288 |
| Principal investigator 1 | ABBVIE INC. | $745.20 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100710290 |
| Principal investigator 1 | ModernaTX, Inc. | $10,811.00 | 03/28/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192080 |
| Principal investigator 1 | ModernaTX, Inc. | $1,927.80 | 03/21/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192078 |
| Principal investigator 1 | ABBVIE INC. | $1,854.00 | 03/14/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100708521 |
| Principal investigator 1 | ModernaTX, Inc. | $14,511.15 | 03/08/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | No dispute reported | 06/30/2026 | 1147154025 |
| Principal investigator 1 | ABBVIE INC. | $20,656.35 | 03/07/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100707444 |
| Principal investigator 1 | Corium, LLC | $13,836.72 | 03/06/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Efficacy and Safety Study w/ Azstarys in Children With ADHD | No dispute reported | 06/30/2026 | 1118399850 |
| Principal investigator 1 | Corium, LLC | $22,981.50 | 03/06/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Safety/Tolerability and PK Study With Azstarys in Children With ADHD (KP415P02) | No dispute reported | 06/30/2026 | 1118399892 |
| Principal investigator 1 | ModernaTX, Inc. | $2,412.15 | 02/09/2024 | Non-covered Recipient Entity IRESEARCH SAVANNAH LLC | A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | No dispute reported | 06/30/2026 | 1147154021 |
| Principal investigator 1 | ABBVIE INC. | $4,969.00 | 02/02/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD | No dispute reported | 06/30/2026 | 1100702620 |
| Principal investigator 1 | Corium, LLC | $30,550.89 | 02/01/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | An Efficacy and Safety Study w/ Azstarys in Children With ADHD | No dispute reported | 06/30/2026 | 1118399848 |
| Principal investigator 1 | PFIZER INC. | $9,167.00 | 01/31/2024 | Non-covered Recipient Entity CenExel iResearch LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1131108614 |
| Principal investigator 1 | ModernaTX, Inc. | $66.24 | 01/10/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease | No dispute reported | 06/30/2026 | 1147192054 |
| Principal investigator 1 | Amgen Inc. | $8,047.76 | 01/09/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Ph3 Pediatric CM Study | No dispute reported | 06/30/2026 | 1096315015 |
| Principal investigator 1 | Amgen Inc. | $9,547.03 | 01/09/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | Phase P3 Pediatric Study EM | No dispute reported | 06/30/2026 | 1096315461 |
| Principal investigator 1 | Eli Lilly and Company | $66,530.00 | 01/02/2024 | Non-covered Recipient Entity CENEXEL IRESEARCH LLC | A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | No dispute reported | 06/30/2026 | 1137356060 |